PARP1 and cytomegalovirus infection: We initially employed Olaparib (PARPi) and pDD00017273 (PARGi), small molecular inhibitors against PARP-1 and PARG, respectively, to investigate the role of PARP-1 and protein PARylation on HCMV infection.